143 related articles for article (PubMed ID: 7470579)
1. Changes of the blood lymphocyte population in cancer patients treated with bestatin, a new immunomodulator. A phase I study.
Blomgren H; Strender LE; Edsmyr F
Biomedicine; 1980 Dec; 32(4):178-85. PubMed ID: 7470579
[TBL] [Abstract][Full Text] [Related]
2. Partial review of immunotherapeutic pharmacology in stem cell transplantation.
Bierman PJ; Abe F; Buyukberber S; Ino K; Talmadge JE
In Vivo; 2000; 14(1):221-36. PubMed ID: 10757081
[TBL] [Abstract][Full Text] [Related]
3. Bestatin treatment and the peripheral lymphocyte population in cancer patients.
Blomgren H; Strender LE; Edsmyr F
Recent Results Cancer Res; 1980; 75():133-8. PubMed ID: 7232824
[TBL] [Abstract][Full Text] [Related]
4. Immunological and haematological monitoring in bladder cancer patients receiving adjuvant bestatin treatment following radiation therapy. A prospective randomized trial.
Blomgren H; Edsmyr F; Esposti PL; Näslund I
Biomed Pharmacother; 1984; 38(3):143-9. PubMed ID: 6383491
[TBL] [Abstract][Full Text] [Related]
5. Bestatin treatment enhances the recovery of radiation induced impairments of the immunological reactivity of the blood lymphocyte population in bladder cancer patients.
Blomgren H; Edsmyr F; von Stedingk LV; Wasserman J
Biomed Pharmacother; 1986; 40(2):50-4. PubMed ID: 3756312
[TBL] [Abstract][Full Text] [Related]
6. Bestatin treatment of human lymphocytes increases the frequency of sheep red blood cell-binding cells.
Blomgren H; Wasserman J
Cancer Lett; 1981 Feb; 11(4):303-8. PubMed ID: 7296523
[TBL] [Abstract][Full Text] [Related]
7. Influence of Bestatin, a new immunomodulator, on various functions of human monocytes.
Jarstrand C; Blomgren H
J Clin Lab Immunol; 1982 Dec; 9(3):193-8. PubMed ID: 7166751
[TBL] [Abstract][Full Text] [Related]
8. Bestatin, a new immunomodulator, augments the release of mitogenic factors from PHA-stimulated human lymphocytes.
Blomgren H
Biomedicine; 1981 Dec; 34(4):188-92. PubMed ID: 6979352
[TBL] [Abstract][Full Text] [Related]
9. [The immunomodulating action of bestatin in the combined therapy of bladder cancer patients].
Neprina GS; Panteleeva ES; Vatin OE; Kariakin OB
Urol Nefrol (Mosk); 1994; (2):34-8. PubMed ID: 8017004
[TBL] [Abstract][Full Text] [Related]
10. [Experimental and clinical studies of bestatin as an immunomodulator].
Miwa H; Oka T; Tsurumi T; Sakae Y; Orita K
Gan To Kagaku Ryoho; 1982 Jul; 9(6):1019-24. PubMed ID: 7184437
[TBL] [Abstract][Full Text] [Related]
11. Immunomodulating properties of bestatin in cancer patients. A phase II trial.
Mathé G; Umezawa H; Misset JL; Brienza S; Canon C; Musset M; Reizenstein P
Biomed Pharmacother; 1986; 40(10):379-82. PubMed ID: 3495299
[TBL] [Abstract][Full Text] [Related]
12. Restoration of E-rosette formation by bestatin in patients with bladder cancer.
Yokoyama H; Umeda T; Kobayashi K; Akaza H; Niijima T
J Cancer Res Clin Oncol; 1980; 98(2):195-201. PubMed ID: 7217183
[TBL] [Abstract][Full Text] [Related]
13. [Phase I study of Bestatin: (I) A clinical study on determination of an optimal dose of Bestatin].
Saito K; Miyasato H; Tajima K; Ikeda S
Gan To Kagaku Ryoho; 1983 Feb; 10(2 Pt):211-7. PubMed ID: 6881973
[TBL] [Abstract][Full Text] [Related]
14. [Initial results of the clinical use of the immunostimulant bestatin (3-amino-2-hydroxy-4-phenylbutyryl leucine) in patients with chronic polyarthritis].
Meske S; Vogt P; Maly FE; Seitz M; Müller W
Z Rheumatol; 1985; 44(5):231-6. PubMed ID: 4082790
[TBL] [Abstract][Full Text] [Related]
15. In vitro augmentation of cytotoxic activity of peripheral blood lymphocytes and spleen cells of cancer patients by ubenimex.
Iwahashi M; Tanimura H; Yamaue H; Tsunoda T; Tani M; Noguchi K; Mizobata S; Tamai M; Hotta T; Arii K
Anticancer Res; 1994; 14(4A):1557-62. PubMed ID: 7979185
[TBL] [Abstract][Full Text] [Related]
16. [Determination of active T lymphocytes in the peripheral blood by the AE rosette test. Correlation of the AE and E rosette tests with lymphocyte reactivity in vitro after PHA stimulation].
Karwowska W; Kunicka A
Probl Med Wieku Rozwoj; 1982; 11():111-6. PubMed ID: 6983690
[TBL] [Abstract][Full Text] [Related]
17. Long-term effects on the immune system following local radiation therapy for breast cancer. III. Changes of spontaneous and lectin dependent cellular cytotoxicity.
Rotstein S; Blomgren H; Petrini B; Wasserman J; Baral E
Anticancer Res; 1986; 6(1):113-8. PubMed ID: 3513692
[TBL] [Abstract][Full Text] [Related]
18. [A new antitumor drug with immunomodulating activity, ubenimex (bestatin)].
Tsukagoshi S
Gan To Kagaku Ryoho; 1987 Jul; 14(7):2385-91. PubMed ID: 3496857
[TBL] [Abstract][Full Text] [Related]
19. Aminopeptidase inhibitor ubenimex (bestatin) inhibits the growth of human choriocarcinoma in nude mice through its direct cytostatic activity.
Inoi K; Goto S; Nomura S; Isobe K; Nawa A; Okamoto T; Tomoda Y
Anticancer Res; 1995; 15(5B):2081-7. PubMed ID: 8572606
[TBL] [Abstract][Full Text] [Related]
20. [Study on the antitumor effect of an inhibitor against cell surface enzyme (Bestatin)].
Sonoyama T; Terata N; Matsumoto H; Nozaki A; Kimura K; Kurioka H; Hashimoto I; Tsunoda F; Kodama M
Nihon Gan Chiryo Gakkai Shi; 1982 Aug; 17(5):1264-9. PubMed ID: 6984058
[No Abstract] [Full Text] [Related]
[Next] [New Search]
